Recursion Pharmaceuticals dropped phase 1b/2 results Monday for REC-4881, a MEK inhibitor it flagged through AI screens. In 12 older patients (55 years old and older) with familial adenomatous polyposis, the drug trimmed total polyp burden a median 43% after three months. The gains stuck around: 12 weeks off treatment, the median drop climbed to…